

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Kenji SASAKI et al. Confirmation No: 5026  
Appl. No. : 10/539,756 Group Art Unit: 1615  
(National Stage of PCT/JP2003/016362)  
I. A. Filed : December 19, 2003 Examiner: Anne M. Gussow  
For : METHOD FOR PROTECTING THIOL GROUP OF PROTEIN

**SUBMISSION OF TERMINAL DISCLAIMER**


Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Window, Mail Stop Amendment  
Recordation Services  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

Further to the filing on March 16, 2009, Applicants submit herewith the executed Terminal Disclaimer. Applicants note that this Terminal Disclaimer differs from the unexecuted version filed on March 16, 2009, in that it has been modified to be executed by a representative for Applicants.

Applicants invite the Examiner to contact the undersigned attorney with any questions.

Respectfully submitted,  
Kenji SASAKI et al.

  
Bruce H. Bernstein  
Reg. No. 29,027 42,920

March 23, 2009  
GREENBLUM & BERNSTEIN, P.L.C.  
1941 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Kenji SASAKI et al. **Confirmation No: 5026**  
Appl. No. : 10/539,756 Group Art Unit: 1615  
(National Stage of PCT/JP2003/016362)  
I. A. Filed : December 19, 2003 Examiner: Anne M. Gussow  
For : METHOD FOR PROTECTING THIOL GROUP OF PROTEIN

**TERMINAL DISCLAIMER**

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Window, Mail Stop Amendment  
Recordation Services  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

Your petitioner, Mitsubishi Tanabe Pharma Corporation, having a business address of 2-10, Dosho-Machi 3-Chome, Chuo-Ku, Osaka-Shi, Osaka, Japan, represents that it is the owner of record of the entire right, title, and interest of the above-identified application by virtue of an assignment from the inventors to Mitsubishi Pharma Corporation, recorded in the U.S. Patent and Trademark Office on April 14, 2006, at Reel 017789, Frame 0627, for U.S. Application No. 10/539,756 for "METHOD FOR PROTECTING THIOL GROUP OF PROTEIN," and a change of name from Mitsubishi Pharma Corporation to Mitsubishi Tanabe Pharma Corporation, recorded in the U.S. Patent and Trademark Office on April 17, 2008, at Reel 020838, Frame 0701.

Your petitioner, Mitsubishi Tanabe Pharma Corporation, further represents that it is the owner of record of the entire right, title, and interest of U.S. Application No. 10/497,516 by virtue of an assignment from the inventors to Mitsubishi Pharma Corporation, recorded in the U.S. Patent and Trademark Office on January 5, 2005, at Reel 016125, Frame 0634, for U.S. Application No. 10/497,516 for "METHOD OF ACTIVATING PROTEIN," and a change of

name from Mitsubishi Pharma Corporation to Mitsubishi Tanabe Pharma Corporation, recorded in the U.S. Patent and Trademark Office on April 17, 2008, at Reel 020838, Frame 0701.

The undersigned is an attorney or agent of record authorized to act on behalf of the assignee in the filing of this terminal disclaimer.


Your petitioner, Mitsubishi Tanabe Pharma Corporation, hereby disclaims, except as provided below, the terminal part of any patent granted on U.S. Patent Application No. 10/539,756 which would extend beyond the expiration date of any patent that issued from U.S. Patent Application No. 10/497,516, and hereby agrees that any patent so granted on U.S. Patent Application No. 10/539,756 shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patent so granted on U.S. Patent Application No. 10/497,516, this agreement to run with any patent granted on U.S. Patent Application No. 10/539,756 and to be binding upon the grantee, its successors or assigns.

Petitioner does not disclaim any terminal part of any patent granted on U.S. Patent Application No. 10/539,756 prior to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 as presently shortened by any terminal disclaimer of any patent granted on a patent granted on U.S. Patent Application No. 10/497,516 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, is reissued, or is otherwise terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the failure of common ownership stated above.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both under Section 1001, Title 18 of the United States

Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,  
Kenji SASAKI et al.

  
Sean C. Myers-Payne  
Reg. No. 42,920

March 23, 2009  
GREENBLUM & BERNSTEIN, P.L.C.  
1941 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191